Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.
about
Progress in treatment of ANCA-associated vasculitisImmunosuppressive treatment for non-systemic vasculitic neuropathySpotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectivesCurrent and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)The immunopathology of ANCA-associated vasculitisGenetically distinct subsets within ANCA-associated vasculitisDiagnosis and treatment of cerebral vasculitis.An increase of CD83+ dendritic cells ex vivo correlates with increased regulatory T cells in patients with active eosinophilic granulomatosis and polyangiitis.Vasculitis in systemic sclerosis.The downsides of a major medical advanceHigh-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestationsThe presentation and management of granulomatosis with polyangiitis (Wegener's Granulomatosis) in the pediatric airway.Variability of the impact of adverse events on physicians' decision makingUrinary immunoglobulin G to albumin ratio and N-Acetyl-Beta-D-Glucosaminidase as early predictors of therapeutic response in ANCA-associated glomerulonephritis.Successful induction of granulomatosis with polyangiitis with tacrolimus.Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis.Hematuria duration does not predict kidney function at 1 year in ANCA-associated glomerulonephritisCardiac involvement in Wegener's granulomatosis resistant to induction therapy.Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials.Immune mediated diseases and immune modulation in the neurocritical care unitAssociation of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysisPlasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis.Outcome and treatment of elderly patients with ANCA-associated vasculitis.Benefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service.Long-term outcomes in antineutrophil cytoplasmic autoantibody-positive eosinophilic granulomatosis with polyangiitis patients with renal involvement: a retrospective study of 14 Chinese patientsProteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis.Association of the Charlson comorbidity index with renal outcome and all-cause mortality in antineutrophil cytoplasmatic antibody-associated vasculitis.Pulmonary arterial hypertension associated with rare cause of ANCA-associated vasculitis misdiagnosed as idiopathic oneEarly Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal DiseaseValaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial.Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment IndexImproved survival in granulomatosis with polyangiitis: A general population-based study.An approach to the diagnosis and management of systemic vasculitis.Survival of patients with Wegener's granulomatosis diagnosed in Finland in 1981-2000.Androgen deficiency in male patients diagnosed with ANCA-associated vasculitis: a cause of fatigue and reduced health-related quality of life?Overall survival, renal survival and relapse in patients with microscopic polyangiitis: a systematic review of current evidence.Churg-strauss syndrome: an update.The pulmonary vasculitides.Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation.
P2860
Q21195258-129F4FB1-7955-40FB-9837-F7B0D70E86C3Q24246358-52177548-9B10-4893-B403-698344D37B0EQ26776308-7DC2BBE3-627D-4476-BC53-C2077E22FAC8Q27025692-13E87871-8924-43C7-8349-1FCA803F10FAQ28391531-7D723398-DB1E-49D6-ACD7-EBCD864E1E1DQ28943363-93AE38B0-B898-4BCA-B572-AAA82A5BB599Q34156332-74586DA3-A876-4A5A-AF2D-E9DB7874434BQ34157221-E050C41F-91DA-45B8-A610-251CA3861191Q34189036-A23C04F8-11FA-480B-9249-381FC0D96157Q34345029-F54DC8E3-6DD6-4786-80AC-A1A3700C815EQ34500661-3657E7AB-1DCD-479A-8698-1E6D4B3E3633Q34523517-C2438781-2E38-4C1C-8724-D33636AEC79CQ34538062-A4394D59-D4FA-4541-8DB7-345B01587E70Q35069739-B70869C8-A169-46ED-8AA8-BE1937DBF620Q35071121-FE770D36-CF55-45F6-AFEB-A626950EFBDFQ35082362-AD51D6F2-FC20-4D03-9CD4-BD24579F0363Q35222622-32FC3591-46FF-49A0-9349-7E0EB68BAFC8Q35250782-9D97A130-5320-43A2-9C6D-3ACEF419F0E3Q35363729-BCCDFA39-10B6-4DA0-88DD-9981A8B13653Q35729575-C71B876D-9E39-4B51-A5C8-2F0B56B9C7D1Q35754787-64821BDB-0FB9-4F87-B1A9-730441296526Q35810445-B3E36574-44D7-4012-B593-873F4D319696Q35816989-027DE79B-3CE2-42BC-9F7E-89837424BD29Q35836369-C2DD6AD9-C69E-493A-934D-93D28FCFA74BQ36086682-AA99FFAA-495D-4850-B2E9-442941B13479Q36104863-A1AF268B-2B0E-4C17-95FF-58CB126A0484Q36193742-F6B6E45B-E426-49F3-8591-A1CE2A99E7DAQ36318217-61635B89-8EDC-40BD-96A6-63B417855207Q36332824-D87F8C43-FD27-4BA0-A7F1-AFEF256FAB2CQ37037298-20E8A996-983B-4892-A5DC-37598BEB65FAQ37118095-70DB7E5E-6BBD-46EB-88B1-AFC3B573D0AFQ37170449-AFAA8890-1F65-4CC0-A220-F914526DDEDFQ37227906-A43A6A76-938B-463E-9907-30915D0E2817Q37673239-1FDE2B25-4D58-4CEE-AB4E-4C1751C9C818Q37687435-CBF09835-482C-44B7-9D4B-06B45BD671FFQ37691208-CC0E2BFB-B14C-429C-89A9-D9B7A2388A2DQ37853275-17658E45-3542-4F78-BBA2-CE7B3F3554A9Q37921646-618D562B-F448-4F0A-AA2E-179391964737Q38017164-455DDC1B-A619-4E8F-A6D0-7811BACF3831Q38082794-1183D866-AF72-46DC-9C18-72BB9019FB22
P2860
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Outcomes from studies of antin ...... ystemic vasculitis task force.
@en
type
label
Outcomes from studies of antin ...... ystemic vasculitis task force.
@en
prefLabel
Outcomes from studies of antin ...... ystemic vasculitis task force.
@en
P2093
P356
P1476
Outcomes from studies of antin ...... ystemic vasculitis task force.
@en
P2093
B Hellmich
C Mukhtyar
European Vasculitis Study Group (EUVAS)
J W Cohen-Tervaert
P304
P356
10.1136/ARD.2007.071936
P407
P577
2007-10-02T00:00:00Z